# CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1)

> **NCT05164003** · PHASE1 · COMPLETED · sponsor: **Medy-Tox** · enrollment: 30 (actual)

## Conditions studied

- Muscle Spasticity

## Interventions

- **DRUG:** CORETOX®
- **DRUG:** BOTOX®

## Key facts

- **NCT ID:** NCT05164003
- **Lead sponsor:** Medy-Tox
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-17
- **Primary completion:** 2017-09-29
- **Final completion:** 2017-09-29
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05164003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05164003, "CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05164003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*